BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’
AstraZeneca and Ionis announced on Thursday that their late-stage CARDIO-TTRansform trial for eplontersen (Wainua) failed to meet its main goal. Analysts largely viewed the miss as a significant blow to Ionis but not fatal for the company overall. BofA Securities called the failure “a big surprise,” attributing it to changes in the treatment landscape. Raymond … Read more